{"id":44621,"date":"2022-06-02T17:01:15","date_gmt":"2022-06-02T15:01:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/"},"modified":"2022-06-02T17:01:15","modified_gmt":"2022-06-02T15:01:15","slug":"rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/","title":{"rendered":"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population"},"content":{"rendered":"
\n

\nThe multi-center, pivotal DISTALS trial is enabled by TIGERTRIEVER\u2122 13, the smallest and only thrombectomy device designed for distal vessels<\/i><\/b>\n<\/p>\n

<\/a><\/p>\n

YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)–#DISTALS<\/a>—Rapid Medical<\/a>, a leading developer of advanced neurovascular devices, announced today the enrollment of the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke.\n<\/p>\n

\n\u201cEnrolling the first patient in this landmark study is an important milestone for patients,\u201d says Dr. Hannes Nordmeyer<\/a>, Neuroradiology Department head at radprax Neurocenter in Solingen, Germany. \u201cWe know from large vessel ischemic stroke that restoring blood flow to the brain as quickly as possible provides greatly improved outcomes. Now that we have the technology to reach distal strokes with TIGERTRIEVER 13, we must understand the patient benefit in quickly opening smaller blood vessels as well.\u201d\n<\/p>\n

\nThis new frontier for ischemic stroke is pioneered by Rapid Medical\u2019s TIGERTRIEVER\u212213<\/a>, the smallest and only adjustable thrombectomy device available. With TIGERTRIEVER 13\u2019s adjustability and complete visibility, physicians remotely control contact with the vessel and clot. This way, each step of the procedure can be optimized.\n<\/p>\n

\nLess than 10% of ischemic stroke patients receive mechanical thrombectomy, a well-proven treatment that significantly improves patient outcomes. With Rapid Medical’s TIGERTRIEVER 13, the DISTALS Study aims to extend these benefits to an additional 25 \u2013 40% of stroke patients. It focuses on outlying brain territories, such as M3 blood vessels, and allows intervention within 24 hours from symptoms onset.\n<\/p>\n

\nThe news follows an international Investigator\u2019s meeting held with trial site principal investigators in New York City\u2013 including Drs. Jeffrey Saver<\/a> at UCLA in Los Angeles, CA; Rishi Gupta<\/a> at Wellstar Health System in Marietta, GA; David Fiorella<\/a> at Stony Brook University Medical Center in Stony Brook, NY; and Professor Ren\u00e9 Chapot <\/a>at Alfried Krupp Krankenhaus in Essen, Germany. At the event, the world\u2019s leading experts discussed challenges in treating this patient population and optimizing the procedure.\n<\/p>\n

\n\u201cWe are thrilled to have such a powerful team of physician contributors to help advance the field,\u201d elates Dr. Walid Haddad<\/a>, Chief Clinical Officer at Rapid Medical. \u201cWe are gaining deeper insights into stroke and how the device\u2019s novel design can be critical in safely treating these delicate areas of the brain.\u201d\n<\/p>\n

\nIn addition to the first patient enrolled by Dr. Hannes Nordmeyer in Germany, Dr. Elad Levy<\/a> at University at Buffalo Neurosurgery in NY just enrolled the first US patient.\n<\/p>\n

\nAbout Rapid Medical
\n
<\/b>Rapid Medical<\/a> develops the premier, responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical\u2019s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER<\/a>\u212217 and 21, COMANECI<\/a>\u2122, and COLUMBUS\u2122\/DRIVEWIRE<\/a> are CE marked and FDA cleared. TIGERTRIEVER\u212213<\/a> and XL<\/a> are also CE marked. More information is available at www.rapid-medical.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRonen Eckhouse
\n
+972-72-2503331
\n
ronen@rapid-medical.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The multi-center, pivotal DISTALS trial is enabled by TIGERTRIEVER\u2122 13, the smallest and only thrombectomy device designed for distal vessels YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)–#DISTALS—Rapid Medical, a leading developer of advanced neurovascular devices, announced today the enrollment of the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44621","6":"format-standard","7":"category-industry"},"yoast_head":"\nRapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The multi-center, pivotal DISTALS trial is enabled by TIGERTRIEVER\u2122 13, the smallest and only thrombectomy device designed for distal vessels YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)–#DISTALS—Rapid Medical, a leading developer of advanced neurovascular devices, announced today the enrollment of the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-02T15:01:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220602005497\/en\/1474506\/21\/Rapid_Medical_Logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population\",\"datePublished\":\"2022-06-02T15:01:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/\"},\"wordCount\":514,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005497\\\/en\\\/1474506\\\/21\\\/Rapid_Medical_Logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/\",\"name\":\"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005497\\\/en\\\/1474506\\\/21\\\/Rapid_Medical_Logo_RGB.jpg\",\"datePublished\":\"2022-06-02T15:01:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005497\\\/en\\\/1474506\\\/21\\\/Rapid_Medical_Logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005497\\\/en\\\/1474506\\\/21\\\/Rapid_Medical_Logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/","og_locale":"en_US","og_type":"article","og_title":"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population - Pharma Trend","og_description":"The multi-center, pivotal DISTALS trial is enabled by TIGERTRIEVER\u2122 13, the smallest and only thrombectomy device designed for distal vessels YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)–#DISTALS—Rapid Medical, a leading developer of advanced neurovascular devices, announced today the enrollment of the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-02T15:01:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220602005497\/en\/1474506\/21\/Rapid_Medical_Logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population","datePublished":"2022-06-02T15:01:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/"},"wordCount":514,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005497\/en\/1474506\/21\/Rapid_Medical_Logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/","url":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/","name":"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005497\/en\/1474506\/21\/Rapid_Medical_Logo_RGB.jpg","datePublished":"2022-06-02T15:01:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220602005497\/en\/1474506\/21\/Rapid_Medical_Logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220602005497\/en\/1474506\/21\/Rapid_Medical_Logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rapid-medical-enrolls-the-first-patient-in-the-distals-stroke-trial-offering-treatment-to-new-ischemic-stroke-patient-population\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial\u2013Offering Treatment to New Ischemic Stroke Patient Population"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44621"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44621\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}